Apellis Pharmaceuticals Inc (NASDAQ: APLS) is -18.52% lower on its value in year-to-date trading and has touched a low of $23.77 and a high of $64.58 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The APLS stock was last observed hovering at around $25.05 in the last trading session, with the day’s gains setting it 0.95%.
Currently trading at $26.00, the stock is -5.43% and -12.15% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing 3.79% at the moment leaves the stock -22.83% off its SMA200. APLS registered -59.31% loss for a year compared to 6-month loss of -33.16%.
The stock witnessed a -8.74% gain in the last 1 month and extending the period to 3 months gives it a -23.37%, and is -1.25% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.51% over the week and 4.73% over the month.
Apellis Pharmaceuticals Inc (APLS) has around 710 employees, a market worth around $3.26B and $781.37M in sales. Fwd P/E is 102.77. Profit margin for the company is -25.32%. Distance from 52-week low is 9.38% and -59.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.61%).
with sales reaching $197.73M over the same period.The EPS is expected to grow by 39.26% this year, but quarterly earnings will post 10.89% year-over-year. Quarterly sales are estimated to grow 14.74% in year-over-year returns.
The shares outstanding are 124.50M, and float is at 104.48M with Short Float at 16.60%.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 16.39 million shares valued at $628.67 million. The investor’s holdings represent 13.2269 of the APLS Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 11.61 million shares valued at $445.26 million to account for 9.3681 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 11.11 million shares representing 8.9675 and valued at over $426.22 million, while VANGUARD GROUP INC holds 7.9171 of the shares totaling 9.81 million with a market value of $376.29 million.
Apellis Pharmaceuticals Inc (APLS) Insider Activity
A total of 0 insider transactions have happened at Apellis Pharmaceuticals Inc (APLS) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Apellis Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 11 ’25 that DeLong Mark Jeffrey (Chief Business & Strat Officer) sold a total of 363 shares of the company’s common stock. The trade occurred on Feb 11 ’25 and was made at $28.54 per share for $10360.0. Following the transaction, the insider now directly holds 83945.0 shares of the APLS stock.
Still, SEC filings show that on Feb 11 ’25, DeLong Mark Jeffrey (Officer) Proposed Sale 363 shares at an average price of $28.54 for $10360.0. The insider now directly holds shares of Apellis Pharmaceuticals Inc (APLS).
Apellis Pharmaceuticals Inc (APLS): Who are the competitors?
One of the company’s main competitors (and peers) include Profarma Distribuidora de Produtos Farmaceuticos S/A Ord (PFRM3) that is trading 19.18% up over the past 12 months.Joey New York Inc. (JOEY) lies in the list of competitors of the Apellis Pharmaceuticals Inc and is 0.00% lower over the same period from APLS1pm Industries Inc. (OPMZ) is -90.00% down on the 1-year trading charts.
